image

Investors

Corporate Profile

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates that can modulate proteins within the cell.

Filing date Description Form View

Quarterly report which provides a continuing view of a company's financial position

10-Q EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML

Quarterly report which provides a continuing view of a company's financial position

10-Q EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML

Post-effective amendment to an S-Type filing

POS AM View HTML

POSASR

POSASR View HTML

POS EX    

POS EX View HTML

Official notification to shareholders of matters to be brought to a vote ("Proxy")

DEF 14A View HTML

Official notification to shareholders of matters to be brought to a vote ("Proxy")

DEF 14A View HTML

Official notification to shareholders of matters to be brought to a vote ("Proxy")

DEF 14A View HTML

Official notification to shareholders of matters to be brought to a vote ("Proxy")

DEF 14A View HTML

Initial filing by director officer or owner of more than ten percent.

3 View HTML

Data provided by Kaleidoscope.